Memorial Sloan Kettering Cancer Center (MSK) has been fighting cancer cells with immune cells for more than 120 years. Researchers across disciplines including immunologists, geneticists and cell biologists work together to make groundbreaking developments. They create powerful immune therapies, focusing on checkpoint inhibitors and CAR-T cell therapy, to treat various forms of advanced cancer. PICI researchers at MSK push the boundaries in cancer research – not only to improve existing immunotherapies but open doors to new ones. Jedd Wolchok, MD, PhD | Director Marcel van den Brink, MD, PhD | Co-Director All Investigators Related Point of View Guest Post: PICI Catalyzes Scientific Innovation Clinical Trial The AMADEUS Trial Clinical Trial The McGRAW Trial Clinical Trial The PRINCE Trial Announcement PICI Network Researchers to Present #SITC22 Announcement Dana-Farber and Gladstone Institutes Join PICI Network Announcement, Our Impact Parker Institute Researchers Featured at #CICON22 Announcement, Our Impact Latest Pancreatic Cancer Findings Highlighted Announcement, Our Impact #ESMO22 Features Six PICI Network Researchers